1/9
06:01 am
kzr
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
Medium
Report
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
12/17
04:35 pm
kzr
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
04:20 pm
kzr
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.